ID: 6488586
Lisa Beatrice Leypoldt
Publications
- 2024
BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords, L., Schaefers, C., Kamili, A., Hoffmann, C., Cichutek, S., Haag, F., Polywka, S., Bokemeyer, C., Leypoldt, L. B., Alsdorf, W., Schulze zur Wiesch, J. & Weisel, K. C., 01.09.2024, In: HAEMATOLOGICA. 109, 9, p. 3071-3077 7 p.Research output: SCORING: Contribution to journal › Case report › Research › peer-review
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees, M. J., D'Agostino, M., Leypoldt, L. B., Kumar, S., Weisel, K. C. & Gay, F., 06.2024, In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 44, 3, p. e433520Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 01.01.2024, In: J CLIN ONCOL. 42, 1, p. 26-37 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
Krzikalla, D., Laschtowitz, A., Leypoldt, L., Gottwick, C., Averhoff, P., Weidemann, S., Lohse, A. W., Huber, S., Schramm, C., Schwinge, D., Herkel, J. & Carambia, A., 2024, In: CELL MOL GASTROENTER. 17, 1, p. 79-91 13 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Leypoldt, L. B., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M. S., Nogai, A., Khandanpour, C., Runde, V., Jauch, A., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M. A. & Weisel, K. C., 21.09.2023, In: CANCERS. 15, 18, 4667.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2022
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein, M., Wrage, V., Ghandili, S., Mellinghoff, S. C., Brehm, T. T., Leypoldt, L. B., Utz, N., Schrader, R. M., Alsdorf, W., Börschel, N., Bußmann, L., Schönrock, M., Perlick, D., Schön, G., Verpoort, K., Lütgehetmann, M., Schulze Zur Wiesch, J., Weisel, K. C., Bokemeyer, C., Schafhausen, P. & Sinn, M., 13.06.2022, In: CANCER CELL. 40, 6, p. 581-583 3 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
- 2021
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L., 24.11.2021, In: J CLIN MED. 10, 23, 5499.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili, S., Weisel, K. C., Bokemeyer, C. & Leypoldt, L. B., 16.11.2021, In: ONCOL RES TREAT. 44, 12, p. 690-699 10 p.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili, S., Schönlein, M., Lütgehetmann, M., Wiesch, J. S. Z., Becher, H., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L. B., 28.07.2021, In: CANCERS. 13, 15, 3800.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
56/m mit Rückenschmerzen und Konzentrationsstörungen
Leypoldt, L. B. & Weisel, K. C., 12.07.2021, In: ONKOLOGE. 2021, 27 supplement issue 1, p. 27-32Research output: SCORING: Contribution to journal › SCORING: Journal article › Education
Untersuchung von Mechanismen der hepatischen Immuntoleranz im Tiermodell der Experimentellen Autoimmunen Enzephalomyelitis
Leypoldt, L. B., 2021Research output: Book/anthology › Dissertations › Research